| scholarly article | Q13442814 |
| P50 | author | Nicola J Mutch | Q61849089 |
| P2093 | author name string | Nuala A Booth | |
| Steven R Fraser | |||
| P2860 | cites work | Transglutaminase inhibition by 2-[(2-oxopropyl)thio]imidazolium derivatives: mechanism of factor XIIIa inactivation | Q72688338 |
| Factor XIII A subunit-deficient mice developed severe uterine bleeding events and subsequent spontaneous miscarriages | Q73838472 | ||
| Human procarboxypeptidase U, or thrombin-activable fibrinolysis inhibitor, is a substrate for transglutaminases. Evidence for transglutaminase-catalyzed cross-linking to fibrin | Q77387645 | ||
| Monocyte plasminogen activator inhibitor 2 (PAI-2) inhibits u-PA-mediated fibrin clot lysis and is cross-linked to fibrin | Q77812986 | ||
| Subunit structure of human fibrinogen, soluble fibrin, and cross-linked insoluble fibrin | Q33699089 | ||
| Factor XIII deficiency | Q33785637 | ||
| Structural origins of fibrin clot rheology | Q34171813 | ||
| Influence of a natural and a synthetic inhibitor of factor XIIIa on fibrin clot rheology. | Q34171820 | ||
| A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion | Q34293695 | ||
| Congenital alpha(2)-plasmin inhibitor deficiencies: a review | Q34319340 | ||
| TAFIa, PAI-1 and alpha-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots | Q34612650 | ||
| Contribution of fibrin stabilization to clot strength. Supplementation of factor XIII-deficient plasma with the purified zymogen | Q35206931 | ||
| Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor | Q37020020 | ||
| Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis | Q40684825 | ||
| Model thrombi formed under flow reveal the role of factor XIII-mediated cross-linking in resistance to fibrinolysis | Q41904806 | ||
| Cross-linking site in fibrinogen for alpha 2-plasmin inhibitor | Q42201799 | ||
| Progressive cross-linking of fibrin gamma chains increases resistance to fibrinolysis. | Q54191211 | ||
| Viscoelastic properties of ligation-inhibited fibrin clots | Q68538852 | ||
| γ-γ Cross-linking sites in human and bovine fibrin | Q70735278 | ||
| Cross-linking of α2-plasmin inhibitor and fibronectin to fibrin by fibrin-stabilizing factor | Q70968109 | ||
| P433 | issue | 23 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 6371-6374 | |
| P577 | publication date | 2011-04-06 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | The antifibrinolytic function of factor XIII is exclusively expressed through α₂-antiplasmin cross-linking | |
| P478 | volume | 117 |
| Q37615581 | Advances of Coagulation Factor XIII |
| Q33435484 | Alternatives to allogeneic platelet transfusion. |
| Q47177380 | An unmet clinical need: The history of thrombus imaging |
| Q45873332 | Anti-factor XIII A subunit (FXIII-A) autoantibodies block FXIII-A2 B2 assembly and steal FXIII-A from native FXIII-A2 B2. |
| Q38543323 | Basic mechanisms and regulation of fibrinolysis |
| Q38038687 | Biology of Factor XIII and clinical manifestations of Factor XIII deficiency |
| Q38669149 | Biophysical Mechanisms Mediating Fibrin Fiber Lysis. |
| Q28070127 | Bleeding related to disturbed fibrinolysis |
| Q90516253 | Blood coagulation dissected |
| Q91839670 | Clinical Significance of Factor XIII Activity and Monocyte-Derived Microparticles in Cancer Patients |
| Q35672990 | Clinical practice: the bleeding child. Part II: disorders of secondary hemostasis and fibrinolysis |
| Q28114772 | Coagulation Factor XIIIA Subunit Missense Mutations Affect Structure and Function at the Various Steps of Factor XIII Action |
| Q41825512 | Coagulation factor XIIIa substrates in human plasma: identification and incorporation into the clot |
| Q54458544 | Compaction of fibrin clots reveals the antifibrinolytic effect of factor XIII. |
| Q40379238 | Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism |
| Q64097553 | Control of fibrinolytic drug injection via real-time ultrasonic monitoring of blood coagulation |
| Q38779362 | Defective α2 antiplasmin cross-linking and thrombus stability in a case of acquired factor XIII deficiency |
| Q33725847 | Development and validation of a high throughput whole blood thrombolysis plate assay. |
| Q35153828 | Evaluating factor XIII specificity for glutamine-containing substrates using a matrix-assisted laser desorption/ionization time-of-flight mass spectrometry assay. |
| Q45859215 | FXIII: mechanisms of action in the treatment of hemophilia A. |
| Q45873682 | Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking. |
| Q92983737 | Factor XIII deficiency does not prevent FeCl3-induced carotid artery thrombus formation in mice |
| Q89893917 | Factor XIII in plasma, but not in platelets, mediates red blood cell retention in clots and venous thrombus size in mice |
| Q38000164 | Factor XIII is a key molecule at the intersection of coagulation and fibrinolysis as well as inflammation and infection control |
| Q91659606 | Factor XIII topology: organization of B subunits and changes with activation studied with single-molecule atomic force microscopy |
| Q38117741 | Fibrin(ogen) and thrombotic disease |
| Q38543294 | Fibrinogen, red blood cells, and factor XIII in venous thrombosis |
| Q35023065 | Functional factor XIII-A is exposed on the stimulated platelet surface |
| Q37692590 | Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk |
| Q34107034 | Incorporation of albumin fusion proteins into fibrin clots in vitro and in vivo: comparison of different fusion motifs recognized by factor XIIIa. |
| Q53730774 | Inhibition of Fibrinolysis by Coagulation Factor XIII. |
| Q53782006 | Is resistance futile? The role of activated thrombin-activatable fibrinolysis inhibitor resistance in bleeding in factor XI deficiency. |
| Q36745029 | Lytic and mechanical stability of clots composed of fibrin and blood vessel wall components |
| Q43018362 | Microvascular thrombosis, fibrinolysis, ischemic injury, and death after cerebral thromboembolism are affected by levels of circulating α2-antiplasmin |
| Q38688608 | Minimal factor XIII activity level to prevent major spontaneous bleeds |
| Q41287140 | Molecular and Physical Mechanisms of Fibrinolysis and Thrombolysis from Mathematical Modeling and Experiments |
| Q38070913 | New developments in the area of factor XIII. |
| Q38801273 | Newly-Recognized Roles of Factor XIII in Thrombosis |
| Q38840345 | Novel aspects of platelet factor XIII function |
| Q38840348 | Novel mechanisms that regulate clot structure/function |
| Q110013384 | Persistent clotting protein pathology in Long COVID/ Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin |
| Q35690807 | Procoagulant activity in hemostasis and thrombosis: Virchow's triad revisited |
| Q83150402 | Reduced difference of α₂-plasmin inhibitor levels between plasma and serum in patients with severe factor XIII deficiency, including autoimmune hemorrhaphilia due to anti-factor XIII antibodies |
| Q88739316 | Regulation of plasminogen activation on cell surfaces and fibrin |
| Q90521533 | Resolution of Deep Venous Thrombosis: Proposed Immune Paradigms |
| Q90823119 | State of the art in factor XIII laboratory assessment |
| Q38052936 | Substrates of Factor XIII-A: roles in thrombosis and wound healing |
| Q45906428 | The effect of blood coagulation factor XIII on fibrin clot structure and fibrinolysis. |
| Q52718043 | The role of barrels 1 and 2 in the enzymatic activity of factor XIII-A. |
| Q58693392 | Thromboelastometry Identified Alteration of Clot Stabilization and Factor XIII Supplementation Need in a Patient with Decompensated Liver Disease Undergoing Liver Biopsy |
Search more.